{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:41:57Z","timestamp":1783086117067,"version":"3.54.6"},"reference-count":118,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sciences"],"abstract":"<jats:p>Recent advances in psychedelic research have renewed interest in their therapeutic potential for psychiatric disorders characterized by cognitive and behavioral rigidity. This review examines the rationale for using serotonergic psychedelics\u2014particularly 5-HT2A receptor agonists such as psilocybin\u2014in the treatment of eating disorders (EDs), including anorexia nervosa (AN), bulimia nervosa (BN), and binge eating disorder (BED). The paper contextualizes these interventions within the broader serotonin hypothesis of EDs, emphasizing serotonergic dysregulation and impaired cognitive flexibility as central features of these conditions. Drawing from animal models, human neuroimaging studies, and emerging clinical trials, the authors outline how psychedelics may promote neuroplasticity and psychological insight through modulation of 5-HT2A signaling. Preliminary evidence from open-label studies suggests psilocybin may improve ED symptoms and quality of life, though findings are early and methodologically limited. The paper also reviews data on ayahuasca, MDMA, and non-psychedelic serotonergic agents, highlighting both the promise and complexity of psychedelic-assisted therapy in EDs. The authors conclude that while further controlled trials are needed to clarify efficacy, safety, and optimal treatment parameters, psychedelics offer a novel, mechanistically distinct avenue for addressing entrenched ED psychopathology.<\/jats:p>","DOI":"10.3390\/brainsci15080893","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T12:31:26Z","timestamp":1755865886000},"page":"893","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Psychedelics and the Serotonin Hypothesis of Eating Disorders"],"prefix":"10.3390","volume":"15","author":[{"given":"Dean","family":"Bilenker","sequence":"first","affiliation":[{"name":"SunCloud Health, Chicago, IL 60614, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"Avena","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY 10021, USA"},{"name":"Department of Psychology, Princeton University, Princeton, NJ 08540, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.neuron.2019.02.005","article-title":"Ketamine: A Paradigm Shift for Depression Research and Treatment","volume":"101","author":"Krystal","year":"2019","journal-title":"Neuron"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1073\/pnas.89.5.1817","article-title":"The Molecular Mechanism of \u201cEcstasy\u201d [3,4-Methylenedioxy-Methamphetamine (MDMA)]: Serotonin Transporters Are Targets for MDMA-Induced Serotonin Release","volume":"89","author":"Rudnick","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_4","unstructured":"Grinspoon, L., and Bakalar, J.B. (1998). Psychodelic Drugs Reconsidered, Lindesmith Center. Reprint, 2. print."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","article-title":"Psychedelics and Psychedelic-Assisted Psychotherapy","volume":"177","author":"Reiff","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"ref_6","first-page":"1","article-title":"Chemistry and Structure-Activity Relationships of Psychedelics","volume":"36","author":"Nichols","year":"2018","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF00176847","article-title":"Radioligand Binding Evidence Implicates the Brain 5-HT2 Receptor as a Site of Action for LSD and Phenylisopropylamine Hallucinogens","volume":"94","author":"Titeler","year":"1988","journal-title":"Psychopharmacology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1073\/pnas.1119598109","article-title":"Neural Correlates of the Psychedelic State as Determined by fMRI Studies with Psilocybin","volume":"109","author":"Erritzoe","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jcbs.2019.11.004","article-title":"Psychological Flexibility Mediates the Relations between Acute Psychedelic Effects and Subjective Decreases in Depression and Anxiety","volume":"15","author":"Davis","year":"2020","journal-title":"J. Context. Behav. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.cpr.2010.03.001","article-title":"Psychological Flexibility as a Fundamental Aspect of Health","volume":"30","author":"Kashdan","year":"2010","journal-title":"Clin. Psychol. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.tins.2015.07.003","article-title":"Demystifying Cognitive Flexibility: Implications for Clinical and Developmental Neuroscience","volume":"38","author":"Dajani","year":"2015","journal-title":"Trends Neurosci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1093\/ajcn\/nqy342","article-title":"Prevalence of Eating Disorders over the 2000\u20132018 Period: A Systematic Literature Review","volume":"109","author":"Galmiche","year":"2019","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.physbeh.2005.06.019","article-title":"Brain Imaging of Serotonin after Recovery from Anorexia and Bulimia Nervosa","volume":"86","author":"Kaye","year":"2005","journal-title":"Physiol. Behav."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0006-3223(02)01378-1","article-title":"Reduced 5-HT2A Receptor Binding after Recovery from Anorexia Nervosa","volume":"52","author":"Frank","year":"2002","journal-title":"Biol. Psychiatry"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0893-133X(99)00117-7","article-title":"Serotonin Function Following Remission from Bulimia Nervosa","volume":"22","author":"Wolfe","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.neuropharm.2011.11.010","article-title":"Dysregulation of Brain Reward Systems in Eating Disorders: Neurochemical Information from Animal Models of Binge Eating, Bulimia Nervosa, and Anorexia Nervosa","volume":"63","author":"Avena","year":"2012","journal-title":"Neuropharmacology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/7854_2010_83","article-title":"Cognitive-Behavioral Flexibility in Anorexia Nervosa","volume":"Volume 6","author":"Adan","year":"2010","journal-title":"Behavioral Neurobiology of Eating Disorders"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/eat.10099","article-title":"Temperament and Character Profile of Eating Disorders: A Controlled Study with the Temperament and Character Inventory","volume":"32","author":"Fassino","year":"2002","journal-title":"Int. J. Eat. Disord."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1176\/appi.ajp.160.2.242","article-title":"Childhood Obsessive-Compulsive Personality Traits in Adult Women with Eating Disorders: Defining a Broader Eating Disorder Phenotype","volume":"160","author":"Anderluh","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1001\/archpsyc.1997.01830180015003","article-title":"Risk Factors for Bulimia Nervosa. A Community-Based Case-Control Study","volume":"54","author":"Fairburn","year":"1997","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1001\/archpsyc.56.5.468","article-title":"Risk Factors for Anorexia Nervosa: Three Integrated Case-Control Comparisons","volume":"56","author":"Fairburn","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/eat.20510","article-title":"A High-Fat Diet Prevents and Reverses the Development of Activity-Based Anorexia in Rats","volume":"41","author":"Brown","year":"2008","journal-title":"Int. J. Eat. Disord."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/978-1-61779-458-2_25","article-title":"The Activity-Based Anorexia Mouse Model","volume":"Volume 829","author":"Kobeissy","year":"2012","journal-title":"Psychiatric Disorders"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.physbeh.2017.06.013","article-title":"Impaired Reversal Learning in an Animal Model of Anorexia Nervosa","volume":"179","author":"Allen","year":"2017","journal-title":"Physiol. Behav."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jpsychires.2010.03.001","article-title":"Exploring the Neurocognitive Signature of Poor Set-Shifting in Anorexia and Bulimia Nervosa","volume":"44","author":"Roberts","year":"2010","journal-title":"J. Psychiatr. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jpsychires.2004.03.001","article-title":"Set Shifting in Anorexia Nervosa: An Examination before and after Weight Gain, in Full Recovery and Relationship to Childhood and Adult OCPD Traits","volume":"38","author":"Tchanturia","year":"2004","journal-title":"J. Psychiatr. Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Tchanturia, K., Davies, H., Roberts, M., Harrison, A., Nakazato, M., Schmidt, U., Treasure, J., and Morris, R. (2012). Poor Cognitive Flexibility in Eating Disorders: Examining the Evidence Using the Wisconsin Card Sorting Task. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0028331"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/archpsyc.55.7.603","article-title":"A Controlled Family Study of Anorexia Nervosa and Bulimia Nervosa: Psychiatric Disorders in First-Degree Relatives and Effects of Proband Comorbidity","volume":"55","author":"Lilenfeld","year":"1998","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ajmg.b.32642","article-title":"Genome-Wide Association Study of Cognitive Flexibility Assessed by the Wisconsin Card Sorting Test","volume":"177","author":"Zhang","year":"2018","journal-title":"Am. J. Med. Genet. Part B Neuropsychiatr. Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1037\/0021-843X.103.1.137","article-title":"Personality Variables and Disorders in Anorexia Nervosa and Bulimia Nervosa","volume":"103","author":"Vitousek","year":"1994","journal-title":"J. Abnorm. Psychol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1176\/appi.ajp.157.11.1799","article-title":"Perfectionism in Anorexia Nervosa: Variation by Clinical Subtype, Obsessionality, and Pathological Eating Behavior","volume":"157","author":"Halmi","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1176\/ajp.154.3.313","article-title":"Outcome in Bulimia Nervosa","volume":"154","author":"Keel","year":"1997","journal-title":"Am. J. Psychiatry"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neubiorev.2016.02.008","article-title":"The 5-HT2A Serotonin Receptor in Executive Function: Implications for Neuropsychiatric and Neurodegenerative Diseases","volume":"64","author":"Aznar","year":"2016","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.neuroscience.2016.03.021","article-title":"The Neural Basis of Reversal Learning: An Updated Perspective","volume":"345","author":"Izquierdo","year":"2017","journal-title":"Neuroscience"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1038\/sj.npp.1301584","article-title":"Dissociable Effects of Selective 5-HT2A and 5-HT2C Receptor Antagonists on Serial Spatial Reversal Learning in Rats","volume":"33","author":"Boulougouris","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00213-014-3699-7","article-title":"Activation of Serotonin 5-HT2A Receptors Inhibits High Compulsive Drinking on Schedule-Induced Polydipsia","volume":"232","author":"Navarro","year":"2015","journal-title":"Psychopharmacology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neuroimage.2013.06.063","article-title":"Serotonin 2A Receptors Contribute to the Regulation of Risk-Averse Decisions","volume":"83","author":"Macoveanu","year":"2013","journal-title":"NeuroImage"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41583-021-00428-w","article-title":"Cognitive and Behavioural Flexibility: Neural Mechanisms and Clinical Considerations","volume":"22","author":"Uddin","year":"2021","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/7854_2010_78","article-title":"Serotonin: Imaging Findings in Eating Disorders","volume":"6","author":"Bailer","year":"2011","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"ref_40","first-page":"20","article-title":"Eating Disorders and the Serotonin Connection: State, Trait and Developmental Effects","volume":"29","author":"Steiger","year":"2004","journal-title":"J. Psychiatry Neurosci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/sj.npp.1300430","article-title":"Altered 5-HT2A Receptor Binding after Recovery from Bulimia-Type Anorexia Nervosa: Relationships to Harm Avoidance and Drive for Thinness","volume":"29","author":"Bailer","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.biopsych.2006.07.018","article-title":"Exaggerated 5-HT1A but Normal 5-HT2A Receptor Activity in Individuals Ill with Anorexia Nervosa","volume":"61","author":"Bailer","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1006\/nimg.2002.1239","article-title":"In Vivo Serotonin 5HT2A Receptor Binding and Personality Traits in Healthy Subjects: A Positron Emission Tomography Study","volume":"17","author":"Moresco","year":"2002","journal-title":"NeuroImage"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.biopsych.2005.05.003","article-title":"Increased Dopamine D2\/D3 Receptor Binding After Recovery from Anorexia Nervosa Measured by Positron Emission Tomography and [11C]Raclopride","volume":"58","author":"Frank","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Westwater, M.L., Murley, A.G., Diederen, K.M.J., Carpenter, T.A., Ziauddeen, H., and Fletcher, P.C. (2022). Characterizing Cerebral Metabolite Profiles in Anorexia and Bulimia Nervosa and Their Associations with Habitual Behavior. Transl. Psychiatry, 12.","DOI":"10.1038\/s41398-022-01872-7"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1192\/bjp.146.2.169","article-title":"Suppression of Eating by Fenfluramine in Patients with Bulimia Nervosa","volume":"146","author":"Robinson","year":"1985","journal-title":"Br. J. Psychiatry"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/00002826-200003000-00006","article-title":"Neuropharmacology of Paradoxic Weight Gain with Selective Serotonin Reuptake Inhibitors","volume":"23","author":"Harvey","year":"2000","journal-title":"Clin. Neuropharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/0306-4530(95)00001-5","article-title":"Toward a Unified Theory of Serotonin Dysregulation in Eating and Related Disorders","volume":"20","author":"Brewerton","year":"1995","journal-title":"Psychoneuroendocrinology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S0006-3223(00)01013-1","article-title":"Double-Blind Placebo-Controlled Administration of Fluoxetine in Restricting- and Restricting-Purging-Type Anorexia Nervosa","volume":"49","author":"Kaye","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1001\/jama.295.22.2605","article-title":"Fluoxetine after Weight Restoration in Anorexia Nervosa: A Randomized Controlled Trial","volume":"295","author":"Walsh","year":"2006","journal-title":"JAMA"},{"key":"ref_51","first-page":"425","article-title":"Does Adjunctive Fluoxetine Influence the Post-Hospital Course of Restrictor-Type Anorexia Nervosa? A 24-Month Prospective, Longitudinal Followup and Comparison with Historical Controls","volume":"33","author":"Strober","year":"1997","journal-title":"Psychopharmacol. Bull."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Fluoxetine in the Treatment of Bulimia Nervosa (1992). A Multicenter, Placebo-Controlled, Double-Blind Trial. Fluoxetine Bulimia Nervosa Collaborative Study Group. Arch. Gen. Psychiatry, 49, 139\u2013147.","DOI":"10.1001\/archpsyc.1992.01820020059008"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1176\/appi.ajp.159.1.96","article-title":"A Placebo-Controlled Study of Fluoxetine in Continued Treatment of Bulimia Nervosa after Successful Acute Fluoxetine Treatment","volume":"159","author":"Romano","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.biopsych.2004.11.002","article-title":"Efficacy of Cognitive Behavioral Therapy and Fluoxetine for the Treatment of Binge Eating Disorder: A Randomized Double-Blind Placebo-Controlled Comparison","volume":"57","author":"Grilo","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4088\/JCP.v68n0306","article-title":"Atomoxetine in the Treatment of Binge-Eating Disorder: A Randomized Placebo-Controlled Trial","volume":"68","author":"McElroy","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0028-3908(97)00051-8","article-title":"Serotonin Induces Excitatory Postsynaptic Potentials in Apical Dendrites of Neocortical Pyramidal Cells","volume":"36","author":"Aghajanian","year":"1997","journal-title":"Neuropharmacology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1073\/pnas.95.2.735","article-title":"5-Hydroxytryptamine2A Serotonin Receptors in the Primate Cerebral Cortex: Possible Site of Action of Hallucinogenic and Antipsychotic Drugs in Pyramidal Cell Apical Dendrites","volume":"95","author":"Jakab","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/(SICI)1098-2396(199709)27:1<79::AID-SYN8>3.0.CO;2-A","article-title":"Serotonin 5-HT2A Receptors Are Expressed on Pyramidal Cells and Interneurons in the Rat Cortex","volume":"27","author":"Willins","year":"1997","journal-title":"Synapse"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","article-title":"Psilocybin Induces Rapid and Persistent Growth of Dendritic Spines in Frontal Cortex in Vivo","volume":"109","author":"Shao","year":"2021","journal-title":"Neuron"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics Promote Structural and Functional Neural Plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/s41386-023-01545-z","article-title":"Acute Psilocybin Enhances Cognitive Flexibility in Rats","volume":"48","author":"Olson","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1038\/s41380-024-02439-2","article-title":"Lasting Dynamic Effects of the Psychedelic 2,5-Dimethoxy-4-Iodoamphetamine ((\u00b1)-DOI) on Cognitive Flexibility","volume":"29","author":"Lazari","year":"2024","journal-title":"Mol. Psychiatry"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/s41380-024-02575-9","article-title":"Psilocybin Restrains Activity-Based Anorexia in Female Rats by Enhancing Cognitive Flexibility: Contributions from 5-HT1A and 5-HT2A Receptor Mechanisms","volume":"29","author":"Conn","year":"2024","journal-title":"Mol. Psychiatry"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/pcn.13741","article-title":"Impact of Psilocybin on Cognitive Function: A Systematic Review","volume":"78","author":"Meshkat","year":"2024","journal-title":"Psychiatry Clin. Neurosci."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Doss, M.K., Pova\u017ean, M., Rosenberg, M.D., Sepeda, N.D., Davis, A.K., Finan, P.H., Smith, G.S., Pekar, J.J., Barker, P.B., and Griffiths, R.R. (2021). Psilocybin Therapy Increases Cognitive and Neural Flexibility in Patients with Major Depressive Disorder. Transl. Psychiatry, 11.","DOI":"10.1038\/s41398-021-01706-y"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Nayak, S.M., Jackson, H., Sepeda, N.D., Mathai, D.S., So, S., Yaffe, A., Zaki, H., Brasher, T.J., Lowe, M.X., and Jolly, D.R.P. (2023). Naturalistic Psilocybin Use Is Associated with Persisting Improvements in Mental Health and Wellbeing: Results from a Prospective, Longitudinal Survey. Front. Psychiatry, 14.","DOI":"10.3389\/fpsyt.2023.1199642"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Mason, N.L., Kuypers, K.P.C., Reckweg, J.T., M\u00fcller, F., Tse, D.H.Y., Da Rios, B., Toennes, S.W., Stiers, P., Feilding, A., and Ramaekers, J.G. (2021). Spontaneous and Deliberate Creative Cognition during and after Psilocybin Exposure. Transl. Psychiatry, 11.","DOI":"10.1038\/s41398-021-01335-5"},{"key":"ref_68","first-page":"777","article-title":"Psilocybin in the treatment of anorexia nervosa: The English transition of a French 1959 case study","volume":"179","author":"Verroust","year":"2021","journal-title":"Ann. M\u00e9dico-Psychol. Rev. Psychiatr."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Lafrance, A., Spriggs, M.J., Gukasyan, N., and Peck, S.K. (2024). Beyond the Numbers: Reimagining Healing with Psychedelics for Eating Disorders. J. Eat. Disord., 12.","DOI":"10.1186\/s40337-024-01111-y"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1038\/s41591-023-02455-9","article-title":"Psilocybin Therapy for Females with Anorexia Nervosa: A Phase 1, Open-Label Feasibility Study","volume":"29","author":"Peck","year":"2023","journal-title":"Nat. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"25","DOI":"10.61373\/pp024r.0028","article-title":"Single-Dose Psilocybin Alters Resting State Functional Networks in Patients with Body Dysmorphic Disorder","volume":"1","author":"Zhu","year":"2024","journal-title":"Psychedelics"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e01710","DOI":"10.1002\/brb3.1710","article-title":"Epidemiology of Body Dysmorphic Disorder among Adolescents: A Study of Their Cognitive Functions","volume":"12","author":"Rajabi","year":"2022","journal-title":"Brain Behav."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/eat.20219","article-title":"Comorbidity of Body Dysmorphic Disorder and Eating Disorders: Severity of Psychopathology and Body Image Disturbance","volume":"39","author":"Ruffolo","year":"2006","journal-title":"Int. J. Eat. Disord."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1017\/S0033291719003003","article-title":"Empirically Defining Treatment Response and Remission in Body Dysmorphic Disorder","volume":"51","author":"Enander","year":"2021","journal-title":"Psychol. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jpsychires.2023.03.031","article-title":"Pilot Study of Single-Dose Psilocybin for Serotonin Reuptake Inhibitor-Resistant Body Dysmorphic Disorder","volume":"161","author":"Schneier","year":"2023","journal-title":"J. Psychiatr. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0378-8741(84)90003-5","article-title":"Monoamine Oxidase Inhibitors in South American Hallucinogenic Plants: Tryptamine and Beta-Carboline Constituents of Ayahuasca","volume":"10","author":"McKenna","year":"1984","journal-title":"J. Ethnopharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s002130000606","article-title":"Subjective Effects and Tolerability of the South American Psychoactive Beverage Ayahuasca in Healthy Volunteers","volume":"154","author":"Riba","year":"2001","journal-title":"Psychopharmacology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/10640266.2023.2271201","article-title":"Ayahuasca Ceremony Leaders\u2019 Perspectives on Special Considerations for Eating Disorders","volume":"32","author":"Williams","year":"2024","journal-title":"Eat. Disord."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/02791072.2017.1361559","article-title":"Nourishing the Spirit: Exploratory Research on Ayahuasca Experiences along the Continuum of Recovery from Eating Disorders","volume":"49","author":"Lafrance","year":"2017","journal-title":"J. Psychoact. Drugs"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s40519-018-0619-6","article-title":"An Exploratory Study of Experiences with Conventional Eating Disorder Treatment and Ceremonial Ayahuasca for the Healing of Eating Disorders","volume":"25","author":"Renelli","year":"2020","journal-title":"Eat. Weight Disord."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"110367","DOI":"10.1016\/j.mehy.2020.110367","article-title":"The Potential Use of N-Methyl-3,4-Methylenedioxyamphetamine (MDMA) Assisted Psychotherapy in the Treatment of Eating Disorders Comorbid with PTSD","volume":"146","author":"Brewerton","year":"2021","journal-title":"Med. Hypotheses"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jpsychires.2022.03.008","article-title":"MDMA-Assisted Therapy Significantly Reduces Eating Disorder Symptoms in a Randomized Placebo-Controlled Trial of Adults with Severe PTSD","volume":"149","author":"Brewerton","year":"2022","journal-title":"J. Psychiatr. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1002\/eat.23401","article-title":"The Association of Traumatic Events and Posttraumatic Stress Disorder with Greater Eating Disorder and Comorbid Symptom Severity in Residential Eating Disorder Treatment Centers","volume":"53","author":"Brewerton","year":"2020","journal-title":"Int. J. Eat. Disord."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1176\/appi.ajp.23180001","article-title":"The American Psychiatric Association Practice Guideline for the Treatment of Patients with Eating Disorders","volume":"180","author":"Crone","year":"2023","journal-title":"Am. J. Psychiatry"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40337-020-0277-8","article-title":"Canadian Practice Guidelines for the Treatment of Children and Adolescents with Eating Disorders","volume":"8","author":"Couturier","year":"2020","journal-title":"J. Eat. Disord."},{"key":"ref_87","unstructured":"(2025, July 29). Recommendations|Eating Disorders: Recognition and Treatment|Guidance|NICE. Available online: https:\/\/www.nice.org.uk\/guidance\/ng69\/chapter\/Recommendations#treating-bulimia-nervosa."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0140-6736(99)09062-5","article-title":"Effect of Decreasing Afferent Vagal Activity with Ondansetron on Symptoms of Bulimia Nervosa: A Randomised, Double-Blind Trial","volume":"355","author":"Faris","year":"2000","journal-title":"Lancet"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.4088\/JCP.v64n1109","article-title":"Treatment of Bulimia Nervosa with Topiramate in a Randomized, Double-Blind, Placebo-Controlled Trial, Part 1: Improvement in Binge and Purge Measures","volume":"64","author":"Hoopes","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/eat.20946","article-title":"Duloxetine in the Treatment of Binge Eating Disorder with Depressive Disorders: A Placebo-Controlled Trial","volume":"45","author":"Guerdjikova","year":"2012","journal-title":"Int. J. Eat. Disord."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.2147\/NDT.S109637","article-title":"Lisdexamfetamine in the Treatment of Moderate-to-Severe Binge Eating Disorder in Adults: Systematic Review and Exploratory Meta-Analysis of Publicly Available Placebo-Controlled, Randomized Clinical Trials","volume":"12","author":"Fornaro","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/00004714-198111000-00005","article-title":"A Double-Blind Controlled Trial of Lithium Carbonate Primary Anorexia Nervosa","volume":"1","author":"Gross","year":"1981","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1176\/appi.ajp.2018.18101125","article-title":"Olanzapine Versus Placebo in Adult Outpatients with Anorexia Nervosa: A Randomized Clinical Trial","volume":"176","author":"Attia","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1176\/appi.ajp.2008.07121900","article-title":"Olanzapine in the Treatment of Low Body Weight and Obsessive Thinking in Women with Anorexia Nervosa: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"165","author":"Bissada","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/eat.10115","article-title":"Olanzapine Use as an Adjunctive Treatment for Hospitalized Children with Anorexia Nervosa: Case Reports","volume":"33","author":"Boachie","year":"2003","journal-title":"Int. J. Eat. Disord."},{"key":"ref_96","first-page":"456","article-title":"Zinc Deficiency and Eating Disorders","volume":"50","author":"Humphries","year":"1989","journal-title":"J. Clin. Psychiatry"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/BF03354425","article-title":"Zinc Supplementation in the Treatment of Anorexia Nervosa","volume":"7","author":"Su","year":"2002","journal-title":"Eat. Weight Disord."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00213-024-06598-6","article-title":"In the New Era of Psychedelic Assisted Therapy: A Systematic Review of Study Methodology in Randomized Controlled Trials","volume":"241","author":"Soliman","year":"2024","journal-title":"Psychopharmacology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e2416106122","DOI":"10.1073\/pnas.2416106122","article-title":"Molecular Design of a Therapeutic LSD Analogue with Reduced Hallucinogenic Potential","volume":"122","author":"Tuck","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Lafrance, A., Strahan, E., Bird, B.M., St. Pierre, M., and Walsh, Z. (2021). Classic Psychedelic Use and Mechanisms of Mental Health: Exploring the Mediating Roles of Spirituality and Emotion Processing on Symptoms of Anxiety, Depressed Mood, and Disordered Eating in a Community Sample. J. Humanist. Psychol., 1\u201319.","DOI":"10.1177\/00221678211048049"},{"key":"ref_101","unstructured":"(2025, June 08). Multidisciplinary Association for Psychedelic Studies\u2014MAPS\u2014Psychedelic Research for Psychological Healing. Available online: https:\/\/maps.org\/."},{"key":"ref_102","unstructured":"Keshavan, M. (STAT, 2024). Lykos Therapeutics Cuts 75% of Staff after FDA Rejects MDMA-Assisted Therapy, STAT."},{"key":"ref_103","unstructured":"(2025, July 30). Could MDMA Help Treat PTSD? FDA Advisors Aren\u2019t Convinced by the Evidence Yet. Available online: https:\/\/www.verywellhealth.com\/fda-panel-rejects-mdma-therapy-for-ptsd-8659953."},{"key":"ref_104","unstructured":"(2025, July 30). FDA Advisory Panel Rejects MDMA-Assisted Therapy for PTSD. Available online: https:\/\/www.pharmacytimes.com\/view\/fda-advisory-panel-rejects-mdma-assisted-therapy-for-ptsd."},{"key":"ref_105","unstructured":"Jacobs, A. (The New York Times, 2024). Panel Rejects MDMA-Aided Therapy for PTSD, The New York Times."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","article-title":"Hallucinogens","volume":"101","author":"Nichols","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0376-8716(98)00129-X","article-title":"Do Hallucinogens Cause Residual Neuropsychological Toxicity?","volume":"53","author":"Halpern","year":"1999","journal-title":"Drug Alcohol Depend."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.neubiorev.2020.03.017","article-title":"Long-term effects of psychedelic drugs: A systematic review","volume":"113","author":"Aday","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/7854_2016_457","article-title":"A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD","volume":"36","author":"Halpern","year":"2018","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S2215-0366(19)30533-4","article-title":"Approval of Esketamine for Treatment-Resistant Depression","volume":"7","author":"Singh","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"ref_111","unstructured":"Johnson, J. (2025, June 08). SPRAVATO\u00ae (Esketamine) Approved in the U.S. as the First and Only Monotherapy for Adults with Treatment-Resistant Depression. Available online: https:\/\/www.prnewswire.com\/news-releases\/spravato-esketamine-approved-in-the-us-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depression-302355833.html."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Barnett, B.S. (2025). Esketamine Implementation Challenges in Psychiatry: A Qualitative Analysis of Mental Healthcare Providers\u2019 Social Media Commentary. medRXiv.","DOI":"10.1101\/2025.06.01.25328722"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Lashgari, N.-A., Khalaji, M., Rana, P., Badrabadi, F., Rahnama, M., Nasoori, H., Momeni Roudsari, N., Khosravi Nia, M.M., and Shafaroodi, H. (Mol. Neurobiol., 2025). Psychedelics in the Treatment of Neurologic and Psychiatric Disorders: Coincidence or a New Point of View, Mol. Neurobiol., ahead of print.","DOI":"10.1007\/s12035-025-05097-9"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-024-01462-3","article-title":"N, N-Dimethyltryptamine, a Natural Hallucinogen, Ameliorates Alzheimer\u2019s Disease by Restoring Neuronal Sigma-1 Receptor-Mediated Endoplasmic Reticulum-Mitochondria Crosstalk","volume":"16","author":"Cheng","year":"2024","journal-title":"Alzheimers Res. Ther."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Ordovich-Clarkson, R.D., Jabbour, M., Pelayo, D.A., Lara, D., La Croix, S., Mumman, M., Stukas, S., Anderson, R., Meraz, D., and Bangura, A. (2025). Comparing Psilocybin to Metformin as Neuroprotective Agents against Parkinson\u2019s Dementia: A Systematic Review of Evidence and Efficacy. Prog. Neuropsychopharmacol. Biol. Psychiatry, 136.","DOI":"10.1016\/j.pnpbp.2024.111155"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of Psilocybin versus Escitalopram for Depression","volume":"384","author":"Giribaldi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_117","first-page":"100873","article-title":"Psychedelics, OCD and Related Disorders: A Systematic Review","volume":"41","author":"Graziosi","year":"2024","journal-title":"J. Obs.-Compuls. Relat. Disord."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Zafar, R., Siegel, M., Harding, R., Barba, T., Agnorelli, C., Suseelan, S., Roseman, L., Wall, M., Nutt, D.J., and Erritzoe, D. (2023). Psychedelic Therapy in the Treatment of Addiction: The Past, Present and Future. Front. Psychiatry, 14.","DOI":"10.3389\/fpsyt.2023.1183740"}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/15\/8\/893\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:32:50Z","timestamp":1760034770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/15\/8\/893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":118,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["brainsci15080893"],"URL":"https:\/\/doi.org\/10.3390\/brainsci15080893","relation":{},"ISSN":["2076-3425"],"issn-type":[{"value":"2076-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]}}}